Related Experiment Video
Updated: May 10, 2026
An Orthotopic Bladder Tumor Model and the Evaluation of Intravesical saRNA Treatment
Published on: July 28, 2012
Novel CAR-T Cells Specifically Targeting SIA-CIgG Demonstrate Effective Antitumor Efficacy in Bladder Cancer
Mengting Ding1, Jiaxing Lin1, Caipeng Qin1
1Department of Urology, Peking University People's Hospital, Beijing, 100044, China.
Abstract:
Chimeric Antigen Receptor (CAR) T-cell therapy is a promising cancer treatment method. However, its application in bladder cancer (BC) remains limited, partially because of the absence of appropriate target molecules. Sialylated cancer-derived IgG (SIA-CIgG) is highly expressed in BC and is closely associated with malignant biological behavior. However, its potential as a target for CAR-T cell therapy to treat BC is yet to be established. Here, it is found that SIA-CIgG is highly expressed in most BC samples but displayed limited expression in normal tissues. CAR-T cells specifically targeting SIA-CIgG can effectively lyse BC cells and the cytotoxicity depends on SIA-CIgG expression. Furthermore, SIA-CIgG CAR-T cells demonstrate milder tumor cell lysis and enhanced persistence compared with human epidermal growth factor receptor 2 (HER2) CAR-T cells, which have undergone extensive clinical trials. After repeated tumor antigen challenges, SIA-CIgG CAR-T cells display substantial alterations in both the transcriptome and chromatin accessibility. When combining SIA-CIgG CAR-T cell therapy with FDA-approved drugs to treat BC, the histone deacetylase inhibitor (HDACi), vorinostat, is found to enhance the ablility of CAR-T cells for tumor cell lysis. Therefore, the combination of SIA-CIgG CAR-T cells and vorinostat is promising for BC treatment.
Insights
Chimeric Antigen Receptor (CAR) T-cell therapy shows promise for bladder cancer (BC) using a novel target, sialylated cancer-derived IgG (SIA-CIgG). This approach, combined with vorinostat, enhances CAR-T cell effectiveness against BC.
Area of Science:
- Immunotherapy
- Oncology
- Biochemistry
Background:
- Chimeric Antigen Receptor (CAR) T-cell therapy is a potent cancer treatment, but its use in bladder cancer (BC) is hindered by a lack of suitable targets.
- Sialylated cancer-derived IgG (SIA-CIgG) is overexpressed in BC and linked to disease progression, suggesting its potential as a therapeutic target.
Purpose of the Study:
- To investigate the efficacy of targeting SIA-CIgG with CAR-T cells for bladder cancer treatment.
- To compare SIA-CIgG CAR-T cells with existing HER2 CAR-T cells and evaluate their combination with vorinostat.
Main Methods:
- Generated and tested CAR-T cells targeting SIA-CIgG against BC cell lines and patient samples.
- Assessed CAR-T cell cytotoxicity, persistence, and transcriptional changes post-antigen challenge.
- Evaluated the combination therapy of SIA-CIgG CAR-T cells with the histone deacetylase inhibitor (HDACi) vorinostat.
Main Results:
- SIA-CIgG is highly expressed in BC tissues but minimally in normal tissues, validating it as a specific target.
- SIA-CIgG CAR-T cells effectively lyse BC cells, with efficacy correlating to SIA-CIgG levels.
- SIA-CIgG CAR-T cells exhibited improved persistence and milder tumor lysis compared to HER2 CAR-T cells.
- Vorinostat enhanced the tumor cell lysis capability of SIA-CIgG CAR-T cells.
Conclusions:
- SIA-CIgG is a viable and specific target for CAR-T cell therapy in bladder cancer.
- The combination of SIA-CIgG CAR-T cells with vorinostat presents a promising therapeutic strategy for BC treatment.
